Nothing Special   »   [go: up one dir, main page]

IL157082A0 - A method for identification, isolation and production of antigens to a specific pathogen - Google Patents

A method for identification, isolation and production of antigens to a specific pathogen

Info

Publication number
IL157082A0
IL157082A0 IL15708202A IL15708202A IL157082A0 IL 157082 A0 IL157082 A0 IL 157082A0 IL 15708202 A IL15708202 A IL 15708202A IL 15708202 A IL15708202 A IL 15708202A IL 157082 A0 IL157082 A0 IL 157082A0
Authority
IL
Israel
Prior art keywords
antigens
specific pathogen
isolation
identification
production
Prior art date
Application number
IL15708202A
Other languages
English (en)
Original Assignee
Intercell Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercell Ag filed Critical Intercell Ag
Publication of IL157082A0 publication Critical patent/IL157082A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1041—Ribosome/Polysome display, e.g. SPERT, ARM
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL15708202A 2001-01-26 2002-01-21 A method for identification, isolation and production of antigens to a specific pathogen IL157082A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0013001A AT410798B (de) 2001-01-26 2001-01-26 Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
PCT/EP2002/000546 WO2002059148A2 (fr) 2001-01-26 2002-01-21 Procede d'identification, d'isolation et de production d'antigenes a un pathogene specifique

Publications (1)

Publication Number Publication Date
IL157082A0 true IL157082A0 (en) 2004-02-08

Family

ID=3636418

Family Applications (4)

Application Number Title Priority Date Filing Date
IL15708202A IL157082A0 (en) 2001-01-26 2002-01-21 A method for identification, isolation and production of antigens to a specific pathogen
IL186706A IL186706A (en) 2001-01-26 2007-10-17 Method for identification, isolation and production of antigens to a specific pathogen
IL211038A IL211038A0 (en) 2001-01-26 2011-02-03 A method for identification, isolation and production of antigens to a specific pathogen
IL211037A IL211037A (en) 2001-01-26 2011-02-03 Antigen @ reactant @ with @ serum @ hyper

Family Applications After (3)

Application Number Title Priority Date Filing Date
IL186706A IL186706A (en) 2001-01-26 2007-10-17 Method for identification, isolation and production of antigens to a specific pathogen
IL211038A IL211038A0 (en) 2001-01-26 2011-02-03 A method for identification, isolation and production of antigens to a specific pathogen
IL211037A IL211037A (en) 2001-01-26 2011-02-03 Antigen @ reactant @ with @ serum @ hyper

Country Status (24)

Country Link
US (4) US7968297B2 (fr)
EP (6) EP1355930B1 (fr)
JP (2) JP2004531476A (fr)
KR (4) KR100851728B1 (fr)
CN (2) CN1649894A (fr)
AT (2) AT410798B (fr)
AU (3) AU2002247641B8 (fr)
BR (1) BR0207067A (fr)
CA (2) CA2792244A1 (fr)
CZ (1) CZ20032201A3 (fr)
DE (1) DE60207194T2 (fr)
DK (1) DK1355930T3 (fr)
ES (1) ES2252438T3 (fr)
HU (1) HUP0402048A3 (fr)
IL (4) IL157082A0 (fr)
IS (1) IS6895A (fr)
MX (1) MXPA03006702A (fr)
NO (1) NO20033364L (fr)
NZ (4) NZ551802A (fr)
PL (2) PL214482B1 (fr)
RU (1) RU2289817C2 (fr)
SK (1) SK10492003A3 (fr)
WO (1) WO2002059148A2 (fr)
ZA (1) ZA200305764B (fr)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053180A2 (fr) 2001-01-03 2002-07-11 Willmar Poultry Company, Inc. Compositions immunisantes et leurs procedes d'utilisation
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
CN100359327C (zh) 2001-06-15 2008-01-02 英希比泰克斯公司 识别凝血酶阴性的葡萄球菌和金黄色葡萄球菌的表面蛋白的交叉反应性单克隆抗体和多克隆抗体
GB0200865D0 (en) * 2002-01-16 2002-03-06 Univ Bristol Method
GB2387600A (en) * 2002-04-19 2003-10-22 Pantherix Ltd Pantothenate kinase
CN1649626A (zh) * 2002-10-03 2005-08-03 英特塞尔股份公司 可与触珠蛋白受体配体结合相互作用的分子的用途
PL1601770T3 (pl) 2003-03-04 2010-02-26 Intercell Ag Antygeny Streptococcus pyogenes
ATE449177T1 (de) 2003-03-31 2009-12-15 Intercell Ag Staphylococcus epidermidis antigene
EP2311988A1 (fr) 2003-04-15 2011-04-20 Intercell AG Antigènes de S. pneumoniae
US20060193866A1 (en) * 2003-04-22 2006-08-31 Intercell Ag H pylori antigens
US7438912B2 (en) 2003-05-07 2008-10-21 Intercell Ag S.agalactiae antigens I + II
EP2267006A1 (fr) 2003-05-30 2010-12-29 Intercell AG Antigènes d'entérocoque
US20060188515A1 (en) * 2003-07-24 2006-08-24 Anderson Annaliesa S Polypeptides for inducing a protective immune response against staphylococcus aureus
BRPI0412799A (pt) * 2003-07-24 2006-09-26 Merck & Co Inc imunógeno, composição, ácido nucleico, célula recombinante, métodos para preparar um polipeptìdeo, para induzir um a resposta imune protetora em um paciente e para induzir uma resposta anamnésica em um paciente, e, seqüência de ácido nucleico otimizada de levedura
NZ582566A (en) 2003-09-19 2010-11-26 Epitopix Llc Metal regulated polypeptides and methods of use from campylobacter spp.
CN1918176A (zh) * 2004-02-18 2007-02-21 默克公司 用于诱导针对金黄色葡萄球菌的保护性免疫反应的多肽
US20070172498A1 (en) * 2004-02-27 2007-07-26 Anderson Annaliesa S Polypeptides for inducing a protective immune response against staphyloococcus aureus
JP2005278537A (ja) * 2004-03-30 2005-10-13 Dai Ichi Seiyaku Co Ltd 新規ポリペプチド
JP2008508855A (ja) * 2004-04-27 2008-03-27 インターツェル・アクチェンゲゼルシャフト Ｔｄ抗原
WO2006065272A2 (fr) 2004-05-21 2006-06-22 Idaho Research Foundation, Inc. Procedes permettant de modifier la production d'acide acetique et de favoriser la mort cellulaire chez les bacteries
US20070243205A1 (en) * 2004-05-25 2007-10-18 Anderson Annaliesa S Polypeptides for Inducing a Protective Immune Response Against Staphylococcus Aureus
WO2005120563A2 (fr) * 2004-06-04 2005-12-22 Pharmexa Inc. Induction d'une reponse immunitaire contre des polysaccharides streptococcus pneumoniae
FR2871159A1 (fr) * 2004-06-08 2005-12-09 Abag Sa Nouvelles proteines permettant, notamment, la mise en evidence in vitro et la prevention des infections a staphylocoques a coagulase negative
FR2871237B1 (fr) * 2004-06-08 2011-03-11 Abag Nouveaux polypeptides pour la mise en evidence in vitro et la prevention des infections staphylococciques sur protheses articulaires et autres materiels etrangers implantes
EP1784212A4 (fr) * 2004-07-06 2008-09-17 Merck & Co Inc Polypeptides utilises pour induire une reponse immunitaire protectrice contre le staphylococcus aureus
WO2007001361A2 (fr) * 2004-09-17 2007-01-04 Merck & Co., Inc. Polypeptides pour induire une reponse immunitaire de protection dirigee contre staphylococcus aureus
CA2580137A1 (fr) 2004-09-22 2006-03-30 Glaxosmithkline Biologicals S.A. Composition immunogene
AU2005333603A1 (en) 2004-10-21 2007-01-04 Wyeth Immunogenic compositions of Staphylococcus epidermidis polypeptide antigens
CN101048172A (zh) * 2004-10-29 2007-10-03 英特塞尔股份公司 用于慢性hcv患者的hcv疫苗
JP2008532483A (ja) 2005-01-21 2008-08-21 メルク エンド カムパニー インコーポレーテッド スタヒロコッカス・アウレウスに対する防御免疫応答を誘導するためのポリペプチド
JP2008528512A (ja) 2005-01-21 2008-07-31 エピトピックス，リミティド ライアビリティ カンパニー エルシニアｓｐｐ．ポリペプチド及び使用方法
AU2006214534B2 (en) 2005-02-14 2012-07-19 Epitopix, Llc Polypeptides from Staphylococcus aureus and methods of use
WO2006105653A1 (fr) * 2005-04-04 2006-10-12 Viventia Biotech Inc. Procede et systeme pour l'identification d'antigene
WO2006121664A2 (fr) * 2005-05-05 2006-11-16 Merck & Co., Inc. Polypeptides induisant une reponse immunitaire de protection contre staphylococcus aureus
US20070003954A1 (en) * 2005-05-12 2007-01-04 The Board Of Regents Of The University Of Texas System Protein and antibody profiling using small molecule microarrays
BRPI0613026A2 (pt) * 2005-07-14 2012-01-03 Bharat Biotech Int Ltd composiÇço, fragmento de nucleotÍdeo, constructo de dna recombinante, mÉtodo para produzir proteÍna, composiÇço farmacÊutica e mÉtodo para uso da mesma, formulaÇço, mÉtodo de administrar composiÇço farmacÊutica, mÉtodo de prevenÇço e controle de infecÇÕes associadas a staphylococcus
WO2008019162A2 (fr) * 2006-01-18 2008-02-14 University Of Chicago Compositions et procédés se rapportant à des protéines de bactéries staphylococciques
MX337528B (es) 2006-03-30 2016-03-09 Glaxosmithkline Biolog Sa Composición inmunogénica que comprende un sacárido capsular estafilocócico o-acetilado y una proteína estafilocócica.
GB0610776D0 (en) * 2006-05-31 2006-07-12 Univ Bath Novel applications for staphylococcus aureus Sbi protein
EP2289906A1 (fr) * 2006-09-15 2011-03-02 Intercell AG Antigènes de la Borrelia
US20080102067A1 (en) * 2006-10-25 2008-05-01 Cook Mark E Immunogenic composition
EP1923069A1 (fr) 2006-11-20 2008-05-21 Intercell AG Peptides protecteurs contre S. pneumoniae et compositions, méthodes et utilisations associés
EP1935984A1 (fr) * 2006-12-20 2008-06-25 Unilever N.V. Procédé d'assistance à la conduite et appareil d'assistance à la conduite
CN101610781A (zh) 2007-01-24 2009-12-23 默克公司 用于诱导针对表皮葡萄球菌的保护性免疫应答的多肽
JP2010521965A (ja) * 2007-03-19 2010-07-01 メルク・シャープ・エンド・ドーム・コーポレイション スタフィロコッカス・エピデルミディス（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓｅｐｉｄｅｒｍｉｄｉｓ）に対する防御免疫応答を誘発するポリペプチド
CA2690271A1 (fr) * 2007-06-18 2008-12-24 Intercell Ag Antigenes de chlamydia
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
CA2697538C (fr) 2007-08-31 2019-02-12 University Of Chicago Procedes et compositions associees pour immuniser contre des maladies et des etats staphylococciques des poumons
EP2201098B1 (fr) * 2007-10-18 2013-08-28 Unilever PLC Procédé de production d'un agent moussant
CN101458255B (zh) * 2007-12-14 2013-03-06 武汉大学 丙型肝炎病毒包膜抗原夹心法试剂盒及检测方法
US20090196852A1 (en) * 2008-02-04 2009-08-06 Watkinson D Tobin Compositions and methods for diagnosing and treating immune disorders
DK2268618T3 (en) 2008-03-03 2015-08-17 Novartis Ag Compounds and compositions as TLR aktivitetsmodulatorer
JP2011514167A (ja) 2008-03-17 2011-05-06 インターセル アーゲー 肺炎連鎖球菌（Ｓ．ｐｎｅｕｍｏｎｉａｅ）に対して保護的なペプチドならびにそれに関連する組成物、方法、および使用
WO2009158682A2 (fr) * 2008-06-27 2009-12-30 Watkinson D Tobin Compositions et procédés pour diagnostiquer et traiter des troubles pathogènes
US20100015171A1 (en) * 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
WO2010014304A1 (fr) 2008-07-29 2010-02-04 University Of Chicago Compositions et procédés apparentés à des protéines de bactérie staphylococcique
CA2738793A1 (fr) * 2008-09-30 2010-04-08 University Of Maryland, Baltimore Vaccin protecteur contre des biofilms de staphylococcus aureus renfermant des immunogenes associes a la paroi cellulaire
WO2010042481A1 (fr) * 2008-10-06 2010-04-15 University Of Chicago Compositions et procédés associés aux protéines bactériennes eap, emp, et/ou adsa
JP2012505645A (ja) * 2008-10-16 2012-03-08 ユニリーバー・ナームローゼ・ベンノートシヤープ 消泡剤を含むハイドロフォビン溶液
CN102292104A (zh) 2008-11-26 2011-12-21 默沙东公司 用于诱导抗金黄色葡萄球菌的保护性免疫应答的多肽
US20110229509A1 (en) 2008-11-26 2011-09-22 Mcneely Tessie B Polypeptides for inducing a protective immune response against staphylococcus aureus
SG195555A1 (en) * 2008-12-24 2013-12-30 Emd Millipore Corp Caustic stable chromatography ligands
WO2010089340A2 (fr) 2009-02-05 2010-08-12 Intercell Ag Peptides protecteurs contre e. faecalis, procédés et utilisations liés à ceux-ci
JP2012521441A (ja) * 2009-03-23 2012-09-13 エピトピックス，リミティド ライアビリティ カンパニー ポリペプチド及びグラム陽性ポリペプチドを含有する免疫化組成物並びにこれらの使用方法
KR101773368B1 (ko) 2009-04-03 2017-08-31 유니버시티 오브 시카고 단백질 Ａ(ＳｐＡ) 변이체와 관련된 조성물 및 방법
EP2419129A2 (fr) * 2009-04-14 2012-02-22 Novartis AG Compositions pour l'immunisation contre staphylococcus aureus
CA2704702C (fr) * 2009-06-02 2018-06-12 Unilever Plc Produits aeres cuits au four
US9517263B2 (en) 2009-06-10 2016-12-13 Glaxosmithkline Biologicals Sa Benzonaphthyridine-containing vaccines
WO2010151544A1 (fr) 2009-06-22 2010-12-29 Wyeth Llc Compositions immunogènes d'antigènes de staphylococcus aureus
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
BR112012004806B8 (pt) 2009-09-02 2022-10-04 Novartis Ag composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
WO2011057148A1 (fr) 2009-11-05 2011-05-12 Irm Llc Composés et compositions permettant de moduler l'activité des tlr-7
SG181712A1 (en) 2009-12-15 2012-07-30 Novartis Ag Homogeneous suspension of immunopotentiating compounds and uses thereof
WO2011101465A1 (fr) 2010-02-19 2011-08-25 Intercell Ag Nanoparticules d'ic31
MX341395B (es) 2010-03-23 2016-08-18 Novartis Ag * Compuestos (lipopeptidos basados en cisteina) y composiciones como agonistas de tlr2 usados para el tratamiento de infecciones, inflamaciones, enfermedades respiratorias, etc.
JP2013523818A (ja) 2010-04-05 2013-06-17 ザ・ユニバーシティー・オブ・シカゴ 免疫反応のエンハンサーとしてのプロテインＡ（ＳｐＡ）抗体に関連する組成物および方法
EP3444268B1 (fr) 2010-05-05 2021-12-15 New York University Staphylococcus aureus leukocidins, compositions thérapeutiques et leurs utilisations
AU2011274367B2 (en) 2010-07-02 2015-04-23 The University Of Chicago Compositions and methods related to protein A (SpA) variants
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
US8747858B2 (en) 2010-07-13 2014-06-10 Merck Sharp & Dohme Corp. Staphylococcus aureus surface protein SA1789 and protective vaccine based thereon
EP2614074A1 (fr) 2010-09-09 2013-07-17 The University of Chicago Procédés et compositions impliquant des antigènes staphylococciques protecteurs
WO2012065034A1 (fr) 2010-11-12 2012-05-18 Merck Sharp & Dohme Corp. Vaccins à base de conjugués de peptide énolase, contre staphylococcus aureus
CN102558316B (zh) * 2010-12-30 2015-07-01 上海雅心生物技术有限公司 高稳定性的具抗体结合能力的重组蛋白a及其生产
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
RU2609650C2 (ru) 2011-06-19 2017-02-02 Нью-Йорк Юниверсити Способ ингибирования токсичности лейкоцидина ed staphylococcus aureus у субъекта
CN109893644A (zh) * 2011-06-19 2019-06-18 纽约大学 治疗和预防金黄色葡萄球菌感染及相关病状的方法
EP2773370A4 (fr) 2011-10-31 2016-09-28 Merck Sharp & Dohme Vaccin prophylactique à base de la protéine sa2451 de staphylococcus aureus
WO2013126006A1 (fr) 2012-02-20 2013-08-29 Swedish Orphan Biovitrum Ab (Publ) Polypeptides se fixant au composant c5 du complément humain
CA2910319C (fr) 2012-04-26 2022-06-14 University Of Chicago Antigenes des staphylocoques coagulase et leurs methodes d'utilisation
EP2872173A4 (fr) 2012-07-10 2016-03-23 Merck Sharp & Dohme Vaccin protecteur à base de protéine sa2493 de staphylococcus aureus
RU2526497C2 (ru) * 2012-10-31 2014-08-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Северо-Западный государственный медицинский университет им. И.И. Мечникова" Министерства здравоохарнения и социального развития Российской Федерации Способ определения генотипов золотистого стафилококка
WO2014074540A2 (fr) * 2012-11-06 2014-05-15 Medimmune, Llc Anticorps dirigés contre des déterminants de surface de s. aureus
EP2935324B1 (fr) * 2012-12-20 2019-10-23 MorphoSys AG Anticorps anti-staphylococciques
CN103965336B (zh) * 2013-01-29 2016-08-10 苏州偲聚生物材料有限公司 多肽、包含该多肽的检测器件和检测试剂盒
TR201807340T4 (tr) 2013-02-01 2018-06-21 Glaxosmithkline Biologicals Sa Çan benzeri reseptör agonistleri içeren immünolojik kompozisyonların intradermal yoldan verilmesi.
KR101808223B1 (ko) * 2013-04-25 2017-12-13 주식회사 앱틀라스 자가 절단 카세트를 포함하는 단백질 정제 방법 및 이의 용도
AU2014314214C1 (en) 2013-08-28 2019-01-24 Affibody Ab Binding polypeptides having a mutated scaffold
AU2014314222B2 (en) * 2013-08-28 2018-05-24 Swedish Orphan Biovitrum Ab (Publ) Stable polypeptides binding to human complement C5
CN104558196A (zh) * 2013-10-15 2015-04-29 温州医科大学 基于HBcAg载体的沙眼衣原体主要外膜蛋白表位疫苗及其用途
RU2542396C1 (ru) * 2013-11-06 2015-02-20 Федеральное бюджетное учреждение науки "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Способ и набор для ускоренной лабораторной диагностики коклюшной инфекции
WO2015082536A1 (fr) * 2013-12-03 2015-06-11 Evaxion Biotech Aps Protéines et acides nucléiques utiles dans des vaccins ciblant staphylococcus aureus
CN103694323B (zh) * 2013-12-09 2017-01-18 成都欧林生物科技股份有限公司 金黄色葡萄球菌MntC重组蛋白及其制备方法和应用
US10100093B2 (en) 2013-12-31 2018-10-16 Epitopix Llc Polypeptides and immunizing compositions containing Burkholderia polypeptides and methods of use
JP6634444B2 (ja) * 2014-06-30 2020-01-22 マードック チルドレンズ リサーチ インスティテュート ヘリコバクター治療
CN104569386B (zh) * 2014-12-10 2016-05-11 中国水产科学研究院淡水渔业研究中心 一种罗非鱼源无乳链球菌elisa快速检测试剂盒及其检测方法
BR112017010888A2 (pt) 2014-12-17 2018-02-27 Hoffmann La Roche método para produzir um produto de conjugação enzimática de três polipeptídeos
EP3302532A4 (fr) 2015-06-05 2019-01-09 New York University Compositions et procédés en rapport avec des agents biologiques antistaphylococciques
EP3353314A1 (fr) 2015-09-25 2018-08-01 H. Hoffnabb-La Roche Ag Transamidation utilisant de la sortase a dans des solvants eutectiques profonds
JP6998862B2 (ja) 2015-09-25 2022-02-04 エフ．ホフマン－ラ ロシュ アーゲー 可溶性ソルターゼａ
WO2017050874A1 (fr) 2015-09-25 2017-03-30 F. Hoffmann-La Roche Ag Procédé de production de thioesters utilisant une sortase a
BR112018010676A2 (pt) 2015-11-27 2019-04-09 Enantis S.R.O. polipeptídeo termoestável, uso e meio de cultura
US10166280B2 (en) 2016-06-08 2019-01-01 Epitopix, Llc Polypeptides and immunizing compositions containing Bacillus polypeptides and methods of use
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
US10504742B2 (en) * 2017-05-31 2019-12-10 Asm Ip Holding B.V. Method of atomic layer etching using hydrogen plasma
WO2018237010A2 (fr) 2017-06-20 2018-12-27 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions vaccinales contre streptococcus et leurs méthodes d'utilisation
SG11202007688YA (en) 2018-02-12 2020-09-29 Inimmune Corp Toll-like receptor ligands
US10905738B2 (en) 2018-07-05 2021-02-02 Biozeus Desenvolvimento De Produtos Biofarmacêuticos Synthetic peptides, prodrugs, pharmaceutical compositions and uses
RU2689161C1 (ru) * 2018-10-04 2019-05-24 Федеральное бюджетное учреждение науки "Казанский научно-исследовательский институт эпидемиологии и микробиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Способ получения бактериальных антигенов
CN111110838A (zh) * 2019-12-24 2020-05-08 华南师范大学 一种罗非鱼无乳链球菌疫苗及其制备方法
CN111808977B (zh) * 2020-07-23 2023-06-27 清华大学深圳国际研究生院 一种由snp所引起利福平类抗生素耐药的抗性基因的特异性引物的设计方法及检测方法
WO2022096596A1 (fr) 2020-11-04 2022-05-12 Eligo Bioscience Phages recombinants de cutibacterium acnes, leur procédé de production et leurs utilisations
KR102306010B1 (ko) * 2021-04-07 2021-09-27 씨제이제일제당 (주) 신규한 분지쇄아미노산 투과효소 변이체 및 이를 이용한 l-발린 생산 방법
KR102281369B1 (ko) * 2021-04-07 2021-07-22 씨제이제일제당 (주) 신규한 디히드로리포일 아세틸기전이효소 변이체 및 이를 이용한 l-발린 생산 방법

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2063965T3 (es) * 1989-03-09 1995-01-16 Praxis Biolog Inc Vacunas para haemophilus influenzae no tipificable.
US5980908A (en) * 1991-12-05 1999-11-09 Alfa Laval Ab Bacterial cell surface protein with fibronectin, fibrinogen, collagen and laminin binding ability, process for the manufacture of the protein and prophylactic treatment
US5456907A (en) 1992-01-10 1995-10-10 Helene Curtis, Inc. Cysteamine permanent wave composition and method
EP0857214A1 (fr) * 1995-10-16 1998-08-12 Smithkline Beecham Plc Nouvelle proteine fixant la salive
US6737248B2 (en) * 1996-01-05 2004-05-18 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
CO4600681A1 (es) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
US6380370B1 (en) * 1997-08-14 2002-04-30 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
JP2001526054A (ja) * 1997-12-05 2001-12-18 インターツェル・ビオメディツィーニシェ・フォルシュングス− ウント・エントヴィックルングス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 組合せライブラリーをスクリーニングするための方法および細胞
DE19803453A1 (de) 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
DE1073771T1 (de) * 1998-04-30 2002-06-13 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Neue methode zur selektion von klonen einer expressionsbibliothek mittels "rearraying"
EP1090111A1 (fr) 1998-06-25 2001-04-11 Institut Pasteur Analyse exhaustive d'interactions de proteines virales au moyen d'un criblage a deux hybrides et selection de polypeptides a interaction virale correctement plies
US6610836B1 (en) * 1999-01-29 2003-08-26 Genome Therapeutics Corporation Nucleic acid amino acid sequences relating to Klebsiella pneumoniae for diagnostics and therapeutics
AT407643B (de) * 1999-02-01 2001-05-25 Intercell Biomedizinische Forschungs & Entwicklungs Gmbh Verfahren zur selektion und herstellung von vakzin- und diagnostika-präparationen
US6936258B1 (en) * 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
CA2372464C (fr) 1999-05-05 2012-07-31 Tvw Telethon Institute For Child Health Research Isolation de modulateurs biologiques a partir de banques de fragments de genes presentant une diversite biologique
WO2001011081A2 (fr) * 1999-08-06 2001-02-15 Ivigene Corporation Polynucleotides microbiens exprimes durant l'infection d'un hote
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
WO2001070955A2 (fr) * 2000-03-21 2001-09-27 Elitra Pharmaceuticals, Inc. Identification de genes esentiels dans des procaryotes
ATE249839T1 (de) 2000-06-08 2003-10-15 Intercell Biomedizinische Forschungs & Entwicklungs Gmbh Immunstimulierende oligodeoxynukleotide
GB0014907D0 (en) * 2000-06-20 2000-08-09 Univ Sheffield Antigenic polypeptides
EP1309345A2 (fr) 2000-08-17 2003-05-14 Cistem Biotechnologies GmbH Vaccin comprenant au moins un antigene et un peptide antimicrobien a base de cathelicidine ou un derive de ce peptide
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
WO2002077183A2 (fr) 2001-03-21 2002-10-03 Elitra Pharmaceuticals, Inc. Identification de genes essentiels dans des microorganismes
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
CN100359327C (zh) 2001-06-15 2008-01-02 英希比泰克斯公司 识别凝血酶阴性的葡萄球菌和金黄色葡萄球菌的表面蛋白的交叉反应性单克隆抗体和多克隆抗体
US7410647B2 (en) 2001-08-02 2008-08-12 University Of Sheffield Antigenic polypeptides
BRPI0412799A (pt) 2003-07-24 2006-09-26 Merck & Co Inc imunógeno, composição, ácido nucleico, célula recombinante, métodos para preparar um polipeptìdeo, para induzir um a resposta imune protetora em um paciente e para induzir uma resposta anamnésica em um paciente, e, seqüência de ácido nucleico otimizada de levedura
ATE410798T1 (de) 2005-06-13 2008-10-15 Research In Motion Ltd Elektrischer verbinder und elektrisches system für ein bauteil in einem elektronischen gerät

Also Published As

Publication number Publication date
RU2289817C2 (ru) 2006-12-20
EP2322539A3 (fr) 2011-09-07
NZ565349A (en) 2009-07-31
AT410798B (de) 2003-07-25
AU2002247641B2 (en) 2007-08-23
AU2007234519A1 (en) 2007-12-13
PL214482B1 (pl) 2013-08-30
RU2003125967A (ru) 2005-03-10
ES2252438T3 (es) 2006-05-16
AU2007234519B2 (en) 2009-11-12
CN1649894A (zh) 2005-08-03
EP1355930B1 (fr) 2005-11-09
EP2319861A1 (fr) 2011-05-11
US20110020402A1 (en) 2011-01-27
CA2436057C (fr) 2012-12-18
IS6895A (is) 2003-07-25
MXPA03006702A (es) 2005-04-08
EP1630172A3 (fr) 2006-05-03
SK10492003A3 (sk) 2004-07-07
IL186706A0 (en) 2008-02-09
NO20033364L (no) 2003-09-24
IL211038A0 (en) 2011-04-28
DK1355930T3 (da) 2006-03-06
EP1630172B1 (fr) 2015-06-10
KR100851728B1 (ko) 2008-08-11
KR20080107477A (ko) 2008-12-10
EP1630172A2 (fr) 2006-03-01
IL211037A (en) 2013-07-31
ZA200305764B (en) 2004-07-26
US20050037444A1 (en) 2005-02-17
US7968297B2 (en) 2011-06-28
CZ20032201A3 (en) 2004-03-17
IL186706A (en) 2010-12-30
EP1616876A3 (fr) 2006-04-12
JP2008291035A (ja) 2008-12-04
US20080038287A1 (en) 2008-02-14
WO2002059148A2 (fr) 2002-08-01
CA2792244A1 (fr) 2002-08-01
NZ527440A (en) 2006-02-24
PL367125A1 (en) 2005-02-21
KR20080029016A (ko) 2008-04-02
NZ551802A (en) 2008-04-30
KR100901915B1 (ko) 2009-06-10
EP2322539A2 (fr) 2011-05-18
WO2002059148A8 (fr) 2003-01-16
JP5053933B2 (ja) 2012-10-24
US7771728B2 (en) 2010-08-10
HUP0402048A2 (hu) 2005-01-28
DE60207194D1 (de) 2005-12-15
BR0207067A (pt) 2004-06-15
EP1616876A2 (fr) 2006-01-18
NO20033364D0 (no) 2003-07-25
US8323660B2 (en) 2012-12-04
US8715688B2 (en) 2014-05-06
EP1355930A2 (fr) 2003-10-29
NZ540764A (en) 2008-03-28
US20130034575A1 (en) 2013-02-07
WO2002059148A3 (fr) 2003-07-31
ATA1302001A (de) 2002-12-15
KR20030082574A (ko) 2003-10-22
CN101492496A (zh) 2009-07-29
PL209115B1 (pl) 2011-07-29
PL392964A1 (pl) 2011-01-03
CA2436057A1 (fr) 2002-08-01
IL211037A0 (en) 2011-04-28
HUP0402048A3 (en) 2010-01-28
DE60207194T2 (de) 2006-08-03
JP2004531476A (ja) 2004-10-14
WO2002059148A9 (fr) 2002-10-31
ATE309268T1 (de) 2005-11-15
AU2002247641B8 (en) 2008-03-13
AU2010200549A1 (en) 2010-03-04
KR20090101973A (ko) 2009-09-29
EP2412722A1 (fr) 2012-02-01

Similar Documents

Publication Publication Date Title
IL211037A0 (en) A method for identification, isolation and production of antigens to a specific pathogen
ATE542829T1 (de) Impfstoff
GB0014907D0 (en) Antigenic polypeptides
WO2005066204A3 (fr) Vaccin stimulant la croissance a base d'un epitope neutralisant
WO2002056905A3 (fr) Jeu ordonne d'echantillons d'antigenes moleculaires
ATE384793T1 (de) Chlamydia antigene und entsprechende dna- fragmente und ihre verwendungen
WO2000075336A3 (fr) Fragment proteiques polyepitopiques des proteines e6 et e7 de hpv, leur obtention et leurs utilisations notamment en vaccination
ATE375391T1 (de) Chlamydia-antigene und entsprechende dna- fragmente und deren verwendungen
PT1409692E (pt) Novos péptidos do derivados da proteína g do vírus respiratório sincicial (vrs) e sua utilização numa vacina
WO2002072013A3 (fr) Methode de traitement de malignites par l'induction de reponses immunitaires dans le sang
WO2003074003A3 (fr) Immunogenes destines au traitement de maladies malignes et infectieuses
WO2001043772A3 (fr) Procede et dispositif de fabrication d'un vaccin contre les maladies cancereuses (vaccin tumoral)